NeoGenomics NEO 深 沪
等待开盘 09-17 09:30:00 美东时间
7.99
-0.090
-1.11%
华盛通- 最 高8.15
- 今 开8.07
- 成交量 145.85万股
- 最 低 7.85
- 昨 收 8.08
- 总市值 10.31亿
- 52周最高 19.115
- 市盈率 静 --
- 换手率 1.13%
- 52周最低 4.72
- 委 比 44.93%
- 总股本 1.29亿
- 历史最高 61.57
- 量 比 0.59
- 振 幅 3.71%
- 历史最低 0.96
- 每 手 1
- 风险率 3.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BlackRock converts two mutual funds into active ETFs
Investment manager BlackRock (NYSE:BLK) (NEOE:BLK:CA) announced on Monday the conversion of two mutual funds into active ETFs. The conversion creates iShares Dynamic Equity Active ETF (BDYN) and iShar...
09-15 20:51
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
NEO Battery Materials secures C$4.5 million purchase order
NEO Battery Materials (OTCPK:NBMFF) announced on Friday that it received its first, multi-year purchase order valued at C$4.5 million with an Asian manufacturer specializing in AI-powered mission flig...
09-12 20:54
星巴克，或许将出售中国业务控制权丨消费参考
21世纪经济报道记者贺泓源、实习生李晴 星巴克中国的出售进程走向落定。 9月11日，据媒体报道，凯雷、殷拓、红杉中国、博裕资本正在准备对星巴克中国业务的控股权提...
09-12 10:14
FDA Authorizes NeOnc Technologies To Proceed With Phase IIa/IIb Of NEO212-01 Clinical Trial
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that the
09-10 21:07
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
NeOnc Technologies Holdings, Inc. announced FDA authorization to advance its NEO212-01 clinical trial into Phase IIa/IIb following successful Phase I results. NEO212, a novel oral chemotherapy drug combining Temozolomide with NEO100, aims to overcome limitations of current glioblastoma treatments. The company plans to expand Phase II trials across leading U.S. cancer centers, positioning NEO212 as a potential new standard of care for brain cancer...
09-10 13:00
On September 4, 2025 BTCS Board Approved $50M Share Repurchase Program Over 3-Years
On September 4, 2025, the Board of Directors (the "Board") of BTCS Inc. (the "Company") approved a share repurchase program (the "Repurchase Program"). Under the Repurchase Program, the Company is authorized to
09-08 21:40
Abaxx Technologies and Qingdao International Energy Exchange explore LNG collab
Abaxx Technologies (NEOE:ABXX:CA) (OTCQX:ABXXF) said that Abaxx Exchange and Qingdao International Energy Exchange, a key energy trading platform in China, intend to explore strategic collaboration ...
09-08 15:11
政策赋能脑机接口迎关键转折期，微美全息（WIMI.US）聚力打造产业培育新引擎
获悉，河南首例无线微创植入式脑机接口手术成功实施，曾经的高位截瘫患者在大脑“开机”后，可以凭借“意念”控制身体完成系列自主动作。这标志着河南省脑机接口临床转化取...
09-05 11:01
新泉股份系列二十一-中报点评：全球化加速推进，看好座椅助力下主业中长期韧性【国信汽车】
登录新浪财经APP 搜索【信披】查看更多考评等级 （来源：车中旭霞） 财报点评 《新泉股份系列二十一-中报点评：全球化加速推进，看好座椅助...
09-04 21:49
